121 related articles for article (PubMed ID: 38564431)
21. Nanoparticular CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice.
Lin HT; Chen CC; Chiao DJ; Chang TY; Chen XA; Young JJ; Kuo SC
Int J Biol Macromol; 2021 Dec; 193(Pt B):1885-1897. PubMed ID: 34774590
[TBL] [Abstract][Full Text] [Related]
22. Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys.
Li H; Guo L; Zheng H; Li J; Zhao X; Li J; Liang Y; Yang F; Zhao Y; Yang J; Xue M; Zuo Y; Zhou J; Chen Y; Yang Z; Li Y; Jin W; Shi H; He Z; Li Q; Liu L
Bioconjug Chem; 2021 May; 32(5):1034-1046. PubMed ID: 33951913
[TBL] [Abstract][Full Text] [Related]
23. Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant.
Akache B; Renner TM; Tran A; Deschatelets L; Dudani R; Harrison BA; Duque D; Haukenfrers J; Rossotti MA; Gaudreault F; Hemraz UD; Lam E; Régnier S; Chen W; Gervais C; Stuible M; Krishnan L; Durocher Y; McCluskie MJ
Sci Rep; 2021 Nov; 11(1):21849. PubMed ID: 34750472
[TBL] [Abstract][Full Text] [Related]
24. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
25. Self-assembled ferritin-based nanoparticles elicit a robust broad-spectrum protective immune response against SARS-CoV-2 variants.
Wang W; Meng X; Cui H; Zhang C; Wang S; Feng N; Zhao Y; Wang T; Yan F; Xia X
Int J Biol Macromol; 2024 Apr; 264(Pt 2):130820. PubMed ID: 38484812
[TBL] [Abstract][Full Text] [Related]
26. Preparation of Modified Konjac Glucomannan Nanoparticles and their Application as Vaccine Adjuvants to Promote Ovalbumin-Induced Immune Response in Mice.
Chen N; Zhu P; Du T; Han K; Wang D; Ye J; Xiao S; Ye X; Wang Y
Pharm Res; 2018 Mar; 35(5):105. PubMed ID: 29560565
[TBL] [Abstract][Full Text] [Related]
27. Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2.
Park KS; Bazzill JD; Son S; Nam J; Shin SW; Ochyl LJ; Stuckey JA; Meagher JL; Chang L; Song J; Montefiori DC; LaBranche CC; Smith JL; Xu J; Moon JJ
J Control Release; 2021 Feb; 330():529-539. PubMed ID: 33358977
[TBL] [Abstract][Full Text] [Related]
28. Assessment of adjuvantation strategy of lipid squalene nanoparticles for enhancing the immunogenicity of a SARS-CoV-2 spike subunit protein against COVID-19.
Ho HM; Huang CY; Cheng YJ; Shen KY; Tzeng TT; Liu SJ; Chen HW; Huang CH; Huang MH
Int J Pharm; 2021 Sep; 607():121024. PubMed ID: 34416331
[TBL] [Abstract][Full Text] [Related]
29. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
30. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
[TBL] [Abstract][Full Text] [Related]
31. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
32. CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2.
Laotee S; Duangkaew M; Jivapetthai A; Tharakhet K; Kaewpang P; Prompetchara E; Phumiamorn S; Sapsutthipas S; Trisiriwanich S; Somsaard T; Roytrakul S; Duangkhae P; Ongpipattanakul B; Limpikirati P; Pornputtapong N; Arunmanee W
PLoS One; 2023; 18(7):e0288486. PubMed ID: 37450510
[TBL] [Abstract][Full Text] [Related]
33. Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant.
Zhang N; Ji Q; Liu Z; Tang K; Xie Y; Li K; Zhou J; Li S; Shang H; Shi Z; Zheng T; Yao J; Lu L; Yuan S; Jiang S
Viruses; 2022 Feb; 14(3):. PubMed ID: 35336907
[TBL] [Abstract][Full Text] [Related]
34. A SARS-CoV-2 nanoparticle vaccine based on chemical conjugation of loxoribine and SpyCatcher/SpyTag.
Yan W; Yu W; Shen L; Xiao L; Qi J; Hu T
Int J Biol Macromol; 2023 Dec; 253(Pt 5):127159. PubMed ID: 37778577
[TBL] [Abstract][Full Text] [Related]
35. TLR9 and STING agonists cooperatively boost the immune response to SARS-CoV-2 RBD vaccine through an increased germinal center B cell response and reshaped T helper responses.
Yang JX; Tseng JC; Tien CF; Lee CY; Liu YL; Lin JJ; Tsai PJ; Liao HC; Liu SJ; Su YW; Hsu LC; Chen JK; Huang MH; Yu GY; Chuang TH
Int J Biol Sci; 2023; 19(9):2897-2913. PubMed ID: 37324951
[TBL] [Abstract][Full Text] [Related]
36. Co-delivery of a trimeric spike DNA and protein vaccine with aluminum hydroxide enhanced Th1-dominant humoral and cellular immunity against SARS-CoV-2.
Liao HC; Huang MS; Chiu FF; Chai KM; Liao CL; Wu SC; Chen HW; Liu SJ
J Med Virol; 2023 Aug; 95(8):e29040. PubMed ID: 37635380
[TBL] [Abstract][Full Text] [Related]
37. Evaluating the immunogenicity of gold nanoparticles conjugated RBD with Freund's adjuvant as a potential vaccine against SARS-CoV-2.
Moshref Javadi M; Taghdisi Hosseinzadeh M; Soleimani N; Rommasi F
Microb Pathog; 2022 Sep; 170():105687. PubMed ID: 35917987
[TBL] [Abstract][Full Text] [Related]
38. A COVID-19 vaccine candidate based on SARS-CoV-2 spike protein and immune-stimulating complexes.
Villarraza J; Fuselli A; Gugliotta A; Garay E; Rodríguez MC; Fontana D; Antuña S; Gastaldi V; Battagliotti JM; Tardivo MB; Alvarez D; Castro E; Cassataro J; Ceaglio N; Prieto C
Appl Microbiol Biotechnol; 2023 Jun; 107(11):3429-3441. PubMed ID: 37093307
[TBL] [Abstract][Full Text] [Related]
39. Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity.
Liao HC; Wu WL; Chiang CY; Huang MS; Shen KY; Huang YL; Wu SC; Liao CL; Chen HW; Liu SJ
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563292
[TBL] [Abstract][Full Text] [Related]
40. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice.
Wørzner K; Sheward DJ; Schmidt ST; Hanke L; Zimmermann J; McInerney G; Karlsson Hedestam GB; Murrell B; Christensen D; Pedersen GK
EBioMedicine; 2021 Jan; 63():103197. PubMed ID: 33422991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
